In this issue of the Journal of Infectious
Diseases, Novakovic et al [1] provide the first report of a decline in juvenile-onset recurrent respiratory papillomatosis (JoRRP) attributable to a national quadrivalent human papillomavirus (qHPV) vaccination program in Australia. So eagerly was this outcome anticipated that it led to the establishment of new surveillance strategies [2, 3] . The decline also effectively confirms, as has been long suspected, that JoRRP is a consequence of the transmission of HPV type 6 or 11 from mother to child around the time of birth. A mother would need to be infected with HPV 6 or 11 to transmit the infection to her child. None of the mothers of the children with JoRRP had received the qHPV vaccine before the pregnancy [1] .
Recurrent respiratory papillomatosis (RRP) comes in 2 forms distinguished by the age groups affected and probably the mode by which HPV is aquired [4] . Adult-onset RRP typically emerges in early adulthood, which is around the most common time that HPV is acquired by sexual transmission. By contrast, JoRRP appears in early childhood and usually runs a more aggressive clinical course, perhaps in part because infants have smaller airways or because of immune compromise [4] . Juvenile-onset recurrent respiratory papillomatosis has been attributed to vertical transmission in the mother's birth canal and sometimes in utero during labour. The resultant wart-like lesions of RRP can be very recurrent and typically involve the larynx, but it can extend to the lower respiratory tract including the lungs, compromising the airway in a manner that is occasionally fatal [4] . In a clinical audit of Australian hospitals, 30 children with JoRRP required 375 admissions over an average of 40 months, mainly for ablative treatment of lesions via endoscopy. Surgical complications were common [2] .
Australia has the highest coverage and had the quickest uptake of qHPV vaccination of any country in the world [5] . Therefore, it is not surprising that it is the first country to document a decline in the incidence of JoRRP. Since 2007, publically funded qHPV vaccine has been offered to all schoolgirls age 12-13 years, with a catch-up program for older schoolgirls and all women up to age 26 years. Nationally, coverage of schoolgirls was 83% for the first dose and 70% for the third dose [6] . Schoolboys were added to the vaccination program in 2013. The qHPV vaccine targets HPV types 6 and 11-the causes of anogenital warts and RRP-in addition to the oncogenic types 16 and 18.
Benefits of Australia's national qHPV vaccination program were evident early on: (1) declining HPV prevalence in young women, sufficient to provide herd protection to unvaccinated women [5, 7] ; (2) declining high-grade cervical lesions in the youngest women [5, 8] ; and (3) genital warts approaching elimination in young people [5, 9] . Given the long natural history of HPV-related cancers, however, it will take many more years to document and understand the full benefit of the vaccination program for cervical, vulval, anal, and oropharyngeal cancers attributable to HPV types 16, 18, and others.
Because the median age at presentation is 36 months (range, 6 months to 14.5 years) [2] , JoRRP can be described as a HPV-related disease with an intermediate incubation period. Thus, it was timely for Novakovic et al [1] , working with the Australian Paediatric Surveillance Unit, to document a national decline in the incidence of JoRRP from 2012 to 2016. It is notable that despite the high qHPV vaccination coverage in young Australian women, none of the mothers of the 15 JoRRP-affected children in this study had received the vaccine before their pregnancies, and the 7 JoRRP cases subjected to genotyping were all positive for HPV 6 or 11. These findings are consistent with and reinforce other observations of the effect of the vaccination program on the prevalence of HPV 6 and 11 [7] and the incidence of anogenital warts [5] . Novakovic et al [1] have started us down the path to viewing JoRRP as a vaccine-preventable disease.
E D I T O R I A L C O M M E N T A R Y
The chronic and relapsing nature of JoRRP makes it a miserable and expensive disease to manage. Each case required a mean of at least 11.2 hospital admissions, with 98.4% of these admissions requiring a general anaesthetic [2] . The medical cost of managing an individual JoRRP case in the United States is estimated to be $150 000 (ranging from $72 000 to $387 000), with an estimated 820 incident cases per year. The total estimated cost is $123 million annually, 1.5% of the total cost burden of HPV-associated diseases [10] . Despite its relative rarity, an order of magnitude drop in the incidence of JoRRP in Australia between 2012 and 2016 [1] means that qHPV vaccination is already netting substantial savings in medical costs related to JoRRP, and this is discounting any drop in JoRRP incidence that may have resulted from the qHPV vaccination program before 2012. The small number of children with JoRRP before the vaccination program in Australia seem to have required more hospital admissions than people with anogenital warts, highlighting again just how expensive it is to manage [11] .
Given the restrictions on endoscopy imposed by many health insurance companies in the United States, family bankruptcy can be a further complication of JoRRP. We can only speculate on what the outcomes might be for children with JoRRP in low-income settings with no access to endoscopy.
Traditionally, cost-effectiveness analyses considering HPV vaccination programs have focused on cervical cancer and often only those attributable to HPV 16. However, cervical cancers comprise only 50% of HPV-related cancers, and diseases attributable to HPV 6 and 11 are either very common (warts) or very expensive (JoRRP), with much shorter incubation periods. Cost savings are realized rapidly, at least partially offsetting the cost of the vaccination programs. Perhaps cost-benefit analyses should cast the net more broadly and embrace a wider spectrum of HPV-related diseases that can be prevented by vaccination [10] .
CONCLUSIONS
As a high-income country with an excellent qHPV vaccination coverage, Australia and similar countries have an obligation to fully evaluate the population-level impact of their vaccination programs. Novakovic et al [1] are to be commended for establishing their surveillance system and determining this encouraging trend in the incidence of JoRRP. National and individual vaccine hesitancy remains common [12] and, unless these hesitant countries are persuaded by the ever-expanding benefits of qHPV vaccination, millions of dollars in health spending along with countless unnecessary episodes of disease and death will occur in the coming decades. 
